EF-5 性质
密度 | 1.66±0.1 g/cm3(Predicted) |
---|---|
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:125 mg/mL(413.69 mM) |
形态 | 固体 |
酸度系数(pKa) | 12.32±0.46(Predicted) |
颜色 | 白色至米白色 |
EF-5 用途与合成方法
Overexpression of CYPOR induces similar 2- to 4-fold increases in EF-5 binding and metabolic reduction of tirapazamine and CEN-209 in SiHa and HCT116 cell lines, and similar enhancement of γH2AX formation. EF-5 binding and metabolic reduction of the prodrugs are highly correlated in a panel of 14 hypoxic tumor cell lines.
EF-5 binding is a promising stratification biomarker for benzotriazine-N-oxide bioreductive prodrugs. In HCT116 xenografts, CYPOR overexpression also significantly increases EF-5 binding and CEN-209 reduction, and modification of tumor hypoxia causes similar changes to the bioreductive activation of both agents, resulting in a strong correlation between EF-5 binding and CEN209-induced DNA damage at the individual tumor level. Following intravenous injection of EF-5, binding and detection using a monoclonal antibody in 9L gliomas is specific and oxygen dependent. Detection of binding using fluorescence microscopy can be performed on frozen tissues; tissue sections can be counterstained with haematoxylin and eosin for light microscopic analysis. Alternatively, the distribution of hypoxia in a tumor can be inferred by examining individual tumor cells using flow cytometric techniques.
EF-5 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2025-02-08 | HY-U00118 | EF-5 | 152721-37-4 | 5mg | 900 |
2025-02-08 | HY-U00118 | EF-5 | 152721-37-4 | 10mM * 1mLin DMSO | 990 |